Switch to:
More From Other Websites
It’s Time to Buy This Biotech Gem Feb 04 2016
Headline Risk Is Poison for Pharma and Biotech Feb 03 2016
Pre-Market Pulse on Biotechnology Stocks -- ZIOPHARM Oncology, BioMarin Pharma, PTC Therapeutics,... Feb 01 2016
BioMarin to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on... Jan 28 2016
BioMarin to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on... Jan 28 2016
Changes in BioMarin’s Valuation Multiples Jan 26 2016
Duchenne drug by Cambridge's Catabasis looks safe in early trial Jan 25 2016
Snowstorm Dashes Hopes for Sarepta Drug's Dystrophy Patients Jan 22 2016
The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing A Muscular Dystrophy Drug Jan 21 2016
Muscular Dystrophy Drugs Face New FDA Questions Jan 20 2016
Biotech Stock Roundup: Sarepta Plunges on Briefing Documents, Acorda to Buy Biotie Jan 20 2016
Why BioMarin's Pipeline Could Be Worth $4 Billion-Plus Jan 20 2016
10 Biotech Buys from Credit Suisse Jan 20 2016
Coverage initiated on Biomarin Pharm by Credit Suisse Jan 20 2016
What Are the Potential Drivers of BioMarin? Jan 19 2016
What Are Analysts’ Expectations for BioMarin? Jan 19 2016
​Science, and not patients, will turn the tide for Sarepta's Duchenne drug Jan 19 2016
[$$] Setback for Sarepta Drug, But Approval Still Possible Jan 15 2016
BioMarin's DMD Drug Kyndrisa Receives CRL from the FDA Jan 15 2016


No Entry for this criteria! We are updating our databases daily, please come back later!

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK